Trump Signs Order to Speed Up Psychedelic Drug Access

President Trump Signs Executive Order on Psychedelics

President Donald Trump signed an executive order today aimed at speeding up access to new medical research and treatments based on psychedelic drugs. The move is intended to help those suffering from severe mental illness and depression, with a particular focus on veterans. The order directs the Food and Drug Administration (FDA) to expedite its review of certain psychedelic drugs that have already been designated as breakthrough therapies.

Focus on Veterans and Mental Health Crisis

The administration highlighted the urgent need to address the mental health crisis, especially among veterans. Suicide rates among veterans have been a significant concern, with statistics showing that since 9/11, more veterans have died by suicide than on the battlefield.

President Trump stated that the goal is to bring new hope and see a significant reduction in these numbers. He mentioned receiving calls from individuals, including Joe Rogan, urging action on this issue.

Key Officials and Supporters Present

The signing ceremony included several key figures from the administration and beyond. Among those present were Secretary of Health and Human Services Robert F. Kennedy Jr., FDA Commissioner Dr. Marty McCary, CMS Administrator Dr. Meett Oz, and NIH Director Dr. J.

Baracheria. Also in attendance were Congressman Morgan Latrell and retired US Navy Seal Marcus Latrell, both veterans who have spoken about the challenges faced by service members. Joe Rogan, a prominent podcast host who has advocated for psychedelic therapies, was also present.

“We’re bringing them new hope. I think you’re going to see a big difference and a big reduction in that number,” President Trump said regarding veteran suicide rates.

Expediting Review and Research

The executive order aims to clear bureaucratic hurdles and improve data sharing between the FDA and the Department of Veterans Affairs. It also facilitates faster rescheduling of any psychedelic drugs that gain FDA approval.

This initiative is seen as a significant step, as research into these experimental treatments has been ongoing for some time. The administration believes that these therapies, currently in advanced clinical trials, have shown life-changing potential.

‘Right to Try’ and Drug Pricing Context

President Trump also referenced his previous efforts, including the ‘Right to Try’ law enacted during his first term. This law allows terminally ill patients to access experimental treatments that have not yet received full FDA approval.

He also touched upon his administration’s work on drug pricing, claiming success in lowering prescription drug costs for Americans. He suggested that the success in lowering drug costs is as significant as the current initiative.

Specific Treatments and Research Investments

The order specifically addresses psychedelic drugs designated as breakthrough therapies. One such treatment mentioned is Ibo gain, which a 2024 Stanford University study found led to an 80-90% reduction in depression and anxiety symptoms in special operations veterans with traumatic brain injuries within one month.

In response, both Texas Republican leaders and the federal government are committing $50 million each to Ibo gain research. The order also opens a pathway for Ibo gain to be administered to critically ill patients under the ‘Right to Try’ law.

FDA and HHS Roles

FDA Commissioner Marty McCary announced that the FDA will issue national priority vouchers for serotonin 2A agonists, also known as psychedelics, allowing for approvals in weeks rather than months. He noted that the FDA is also announcing the first Ibo gain investigational new drug clearance, enabling human trials in the U.S. Secretary Kennedy added that HHS will allocate at least $50 million to partner with states advancing these therapies and will strengthen research and data sharing.

“Federal prohibition of psychedelic medicine in America is over,” stated Brian Huggard, CEO of Americans Try again, highlighting the significance of the day.

Personal Testimonials and Future Outlook

Several individuals shared personal stories of how psychedelic treatments have impacted their lives. Marcus Latrell spoke about how Ibo gain changed his life for the better, allowing him to live his best days. Rob O’Neill shared that a psychedelic treatment helped him overcome his addiction to alcohol, saving his life.

Joe Rogan emphasized how conversations on his podcast brought national attention to these treatments, advocating for their potential. The administration expressed commitment to continued research to ensure these therapies are safe and effective, with the goal of providing relief and improving the lives of those suffering from mental health conditions.

Next Steps and Broader Implications

The executive order represents a significant shift in how the U.S. government approaches the research and accessibility of psychedelic therapies. The focus on expediting FDA reviews, increasing research funding, and expanding access through programs like ‘Right to Try’ signals a new era for mental health treatment.

The administration plans to closely monitor the progress of clinical trials and the implementation of these new pathways. The full impact of this order on patient access and scientific understanding is expected to unfold in the coming months and years.

Source: LIVE: Trump holds executive order signing | NBC News (YouTube)